MLL2
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
PE
Applikationshinweise
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:50-300,IF 1:50-200
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 %BSA
Konservierungsmittel
ProClin
Vorsichtsmaßnahmen
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
MLL2
(Myeloid/lymphoid Or Mixed-Lineage Leukemia 2 (MLL2))
Andere Bezeichnung
MLL2
Hintergrund
Histone-lysine N-methyltransferase 2D, Lysine N-methyltransferase 2D, ALL1-related protein, Myeloid/lymphoid or mixed-lineage leukemia protein 2KMT2D (Lysine Methyltransferase 2D) is a Protein Coding gene. Among its related pathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Chromatin organization. The protein encoded by KMT2D is a histone methyltransferase that methylates the Lys-4 position of histone H3. The encoded protein is part of a large protein complex called ASCOM, which has been shown to be a transcriptional regulator of the beta-globin and estrogen receptor genes. Mutations in KMT2D have been shown to be a cause of Kabuki syndrome.